Overview and answer
Addyi is an oral prescription medication indicated to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not an aphrodisiac, hormonal therapy, or a stimulant; rather, it acts on neurotransmitters in the brain to increase sexual desire. Approved by the U.S. Food and Drug Administration (FDA) in 2015, Addyi is intended for use when low sexual desire causes marked distress and relationship difficulty and is not better explained by other medical, mental, or relationship problems. This article explains how Addyi works, its evidence, safety considerations, who may be candidates, and practical points about using it as part of a broader approach to sexual health.
What is Addyi (flibanserin)?
Addyi is the brand name for flibanserin, a non-hormonal oral therapy developed for women experiencing persistent low sexual desire. Marketed as a treatment for hypoactive sexual desire disorder (HSDD), it is intended to address a pattern of low or absent sexual fantasies and desire that causes personal distress or interpersonal strain. Addyi is not intended for women whose low desire is solely due to relationship problems, untreated depression, or other situational factors. Because low sexual desire has many possible causes, a thorough medical evaluation is important before considering Addyi.
How Addyi works in the body and brain
Neurotransmitter activity, not hormones
Addyi does not function like hormones, testosterone, or estrogen, and it does not increase arousal in response to sexual stimulation the way topical products might. Instead, it modulates key neurotransmitters in the central nervous system. It acts as a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist, which influences inhibitory and excitatory pathways related to sexual desire. These actions affect signaling in brain regions involved in reward, motivation, and sexual behavior, but the full physiological mechanisms are still being studied.
Peripheral actions and context
The drug also affects peripheral receptors, including dopamine D2 and D3 receptors, as well as alpha-2 adrenergic and certain opioid receptors, contributing to its overall profile. Because desire is shaped by a mix of central and peripheral factors, Addyi’s mechanism is best described as altering central regulation of sexual motivation rather than directly targeting genital arousal. This is one reason why its effects are often modest and why non-drug approaches are commonly recommended alongside or before pharmacologic options.
FDA approval and regulatory status
Addyi (flibanserin) received FDA approval in 2015 for the treatment of HSDD in premenopausal women. The approval was based on data from two phase 3 clinical trials that showed a small but statistically significant increase in satisfying sexual events compared to placebo. As with any condition treated with daily medication, clinicians typically consider duration of symptoms, severity, and impact on quality of life before prescribing. Because Addyi requires daily dosing and has specific safety requirements around alcohol, it is not suitable for everyone.
Key approval data and context
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Active ingredient | flibanserin | FDA label, prescribing information |
| Indication | Hypoactive sexual desire disorder (HSDD) | FDA label |
| Population studied | Premenopausal women with HSDD | Phase 3 trials supporting approval |
| Treatment approach | Daily oral medication | Prescribing information |
| Onset | Noticeable changes may take several weeks | Clinical trial and label data |
Effectiveness: what the evidence shows
Clinical trials demonstrate that Addyi can modestly increase the frequency of satisfying sexual events, but the magnitude of benefit is often small. Many people notice incremental changes rather than dramatic shifts, and individual responses vary. Benefit is typically assessed over several months of daily use, because the neuroadaptive changes involved are not immediate. For some individuals, the combination of pharmacologic treatment and counseling or behavioral strategies yields the best outcome, whereas others may find non-drug options sufficient.
Safety, side effects, and important precautions
Common and notable side effects
Addyi can cause side effects, and alcohol use while taking it poses serious risks. Because the drug affects serotonin and other systems, combining it with alcohol may lead to severe nausea, vomiting, lightheadedness, and fainting. It is important to stop or avoid alcohol during treatment. Common side effects may include nausea, dizziness, sleepiness, fatigue, and dry mouth. Some people report feeling lightheaded when standing (orthostatic hypotension), especially shortly after taking a dose.
Drug interactions and contraindications
Because Addyi interacts with medications that affect serotonin, liver enzymes, or blood pressure, it is important to disclose all prescription and over-the-counter drugs, including supplements, to your clinician. Addyi is contraindicated in people with certain liver impairments, those taking strong CYP3A4 inhibitors or inducers, and individuals using opioids or some antidepressants without close oversight. A complete medical history and review of medications can help determine whether the benefits outweigh the risks.
Who might consider Addyi and what to expect
Addyi may be considered for premenopausal women with HSDD who have not improved with lifestyle measures, counseling, or treatment of underlying mood or relationship issues. Candidates typically experience persistent low desire that is distressing and not better explained by other factors. Clinicians usually assess frequency and intensity of thoughts about sex, emotional well-being, relationship context, and overall health before recommending daily medication. If Addyi is prescribed, it is often used alongside sexual health counseling and practical strategies to enhance intimacy.
Takeaway summary
Addyi (flibanserin) is an FDA-approved, non-hormonal oral medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by modulating neurotransmitters involved in sexual motivation and reward rather than by altering hormones. Treatment may modestly increase satisfying sexual events over time, but individual results vary, and modest expectations are realistic. Because Addyi requires avoiding alcohol and carries potential side effects and drug interactions, medical evaluation and ongoing supervision are essential. For many people, the best approach combines a thoughtful discussion with a clinician, possible use of Addyi, and non-drug strategies to support sexual and relational well-being.